References
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2.
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF, Feuer E: Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008;19:175-181.
3.
Loeb S, Catalona WJ: Prostate-specific antigen (PSA) should drive doing prostate biopsies. Urol Oncol 2012;30:1-2.
4.
Andriole GL Jr: PSA screening and prostate cancer risk reduction. Urol Oncol 2012;30:936-937.
5.
American Cancer Society: The American Cancer Society's 2013 Cancer Facts & Figures. Atlanta, GA, ACS, 2013, p v.
6.
Robert Koch-Institut: Verbreitung von Krebserkrankungen in Deutschland. Berlin, RKI, 2010.
7.
Moyer VA, U.S. Preventive Services Task Force: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120-134.
8.
Catalona WJ, D'Amico AV, Fitzgibbons WF, Kosoko-Lasaki O, Leslie SW, Lynch HT, Moul JW, Rendell MS, Walsh PC: What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med 2012; 157:137-138.
9.
Kwiatkowski M, Klotz L, Hugosson J, Recker F: Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer. Eur Urol 2012;61:851-854.
10.
Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, Hugosson J: Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol 2012;30:2581-2584.
11.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss 14 SM, de Koning HJ, Auvinen A; ERSPC Investigators: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320-1328.
12.
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-1319.
13.
Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team: Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21(suppl):273S-309S.
14.
Pinsky PF, Parnes HL, Andriole G: Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. BJU Int 2014;113:254-259.
15.
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team: Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125-132.
16.
De Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE; ERSPC: Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002;98:268-273.
17.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-990.
18.
Wolters T, Roobol MJ, Steyerberg EW, van den Bergh RC, Bangma CH, Hugosson J, Ciatto S, Kwiatkowski M, Villers A, Lujan M, Nelen V, Tammela TL, Schroder FH: The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer 2010;126:2387-2393.
19.
Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H: Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-732.
20.
Catalona WJ, Loeb S: The PSA era is not over for prostate cancer. Eur Urol 2005;48:541-545.
21.
Vickers A, Carlsson S, Laudone V, Lilja H: It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening. Eur Urol 2014;DOI: 10.1016/j.eururo. 2013.12.049.
22.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V Wiegel T, Zattoni F, Mottet N: EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent - update 2013. Eur Urol 2014;65:124-137.
23.
Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, van Poppel H, Wirth M, Mottet N: Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol 2013;64:347-354.
24.
Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P: Screening for prostate cancer: systematic review and metaanalysis of randomised controlled trials. BMJ 2010; 341:c4543.
25.
Ilic D, Neuberger MM, Djulbegovic M, Dahm P: Screening for prostate cancer. Cochrane Database Syst Rev 2013;1:CD004720.
26.
Ablin R: The Great Prostate Mistake. The New York Times, March 9, 2010. www.nytimes.com/2010/03/10/opinion/10Ablin.html?_r = 0.
27.
Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P: Randomised PCa screening trial: 20 year follow-up. BMJ 2011;342:d1539.
28.
Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau G, et al.: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004;59:311-318.
29.
Kjellman A, Akre O, Norming U, Törnblom M, Gustafsson O: 15-year follow-up of a population based PCa screening study. J Urol 2009;181:1615-1621.
30.
Gulati R, Tsodikov A, Wever EM, et al.: The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control 2012;23:827-835.
31.
Popiolek M, Rider JR, Andrén O, et al.: Natural history of early, localized PCa: a final report. Eur Urol 2013;63:428-435.
32.
Carlsson S, Aus G, Bergdahl S, et al.: The excess burden of side-effects from treatment in men allocated to screening for PCa. Eur J Cancer 2011;47: 545-553.
33.
Dubben HH: Trials of prostate-cancer screening are not worthwhile. Lancet Oncol 2009;10:294-298.
34.
SGB V §35b. www.gesetze-im-internet.de/sgb_5/_35b.html.
35.
Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ: Overdetection, overtreatment and costs in PSA screening. Br J Cancer 2009;101:1833-1838.
36.
Nationaler Krebsplan, Ziel 1. www.bmg.bund.de/praevention/nationaler-krebsplan/was-haben-wirbisher-erreicht/ziel-1-inanspruchnahme-krebsfrueh-erkennung.html.
37.
Klemperer D, Lang B, Koch K, et al.: Gute Praxis Gesundheitsinformation, Version 1.3 vom 10.03.2009. www.ebm-netzwerk.de/pdf/publikationen/gpgi.pdf.
38.
Elwyn G, O'Connor A, Stacey D, et al.: Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ 2006;333:417.
39.
Wegwarth O, Schwartz LM, Woloshin S, Gaissmaier W, Gigerenzer G: Do physicians understand cancer screening statistics? Ann Intern Med 2012; 156:340-349.
40.
Leitlinienprogramm Onkologie: Früherkennung von Prostatakrebs. Eine Information für Männer. (2012). www.leitlinienprogramm-onkologie.de/fuploads/tx_sbdownloader/Patientenleitlinie_Prostata-krebs_Frueherkennung.pdf
41.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG): Spezial Früherkennung von Prostatakrebs. www.gesundheitsinformation. de/psa-test.1056.56.de.html.
42.
S3-Leitlinie Prostatakarzinom (2011). www.leitlinien-programm-onkologie.de/uploads/tx_sbdownloader/S3-Prostatakarzinom-OL-Langversion.pdf
43.
National Institute for Health and Care Excellence: Prostate Cancer (CG 175), 2014. guidance.nice.org. uk/CG175.
44.
European Association of Urology: Guidelines on Prostate Cancer (2013). www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf.
45.
National Institute of Health: Role of Active Surveillance in the Management of Men with Localized Prostate Cancer (2011). www.consensus.nih. gov/2011/prostate.htm.
46.
Parker C: Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004;5:101-106.
47.
Carter HB, Partin AW, Walsh PC, et al.: Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol 2012;30:4294-4296.
48.
Klotz L: Cancer overdiagnosis and overtreatment. Curr Opin Urol 2012;22:203-209.
49.
Harnden P, Naylor B, Shelley MD, Clements H, Coles B, Mason MD: The clinical management of patients with a small volume of prostatic cancer on biopsy. A systematic review and meta-analysis. Cancer 2008;112:971-981.
50.
Vickers AJ, Ulmert D, Sjoberg DD, et al.: Strategy for detection of PCa based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis. BMJ 2013;346:f2023.
51.
Vickers AJ, Cronin AM, Björk T, et al.: Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer. BMJ 2010;341:c4521.
52.
Lilja H, Cronin AM, Dahlin A, et al.: Prediction of significant PCa diagnosed 20 to 30 years later. Cancer 2011;117:1210-1219.
53.
Draisma G, Etzioni R, Tsodikov A, et al.: Lead time and overdiagnosis in prostate-specific antigen screening. J Natl Cancer Inst 2009;101:374-383.
54.
Maio G: Mittelpunkt Mensch: Ethik in der Medizin. Stuttgart, Schattauer, 2012, pp 376-383.
55.
Vickers AJ, Lilja H: PSA is dead, long live PSA. Eur Urol 2012;61:467-468; discussion 469-470.
56.
Andriole GL: Update of the prostate, lung, colorectal, and ovarian cancer screening trial. Recent Results Cancer Res 2014;202:53-57.
57.
Black WC, Haggstrom DA, Welch HG: All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002;94:167-173.
58.
Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH. Baseline prostate-specific antigen testing at a young age. Eur Urol 2012;61:1-7.
59.
Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE: Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. Eur Urol 2012; 61:865-874.
60.
Borgermann C, vom Dorp F, Swoboda A, Ketteniss O, Becker M, Rubben H: PSA quo vadis? It is reasonable to start with prostate-specific antigen testing at the age of 40! Cancer Epidemiol Biomarkers Prev 2011;20:1190-1195.
61.
Connolly D, Black A, Gavin A, Keane PF, Murray LJ: Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Cancer Epidemiol Biomarkers Prev 2008;17:271-278.
62.
Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, Carter HB: PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol 2008;54:1073-1080.
63.
Grubb RL 3rd, Andriole GL: Can preoperative PSA doubling time and PSA velocity predict outcomes following radical prostatectomy? Nat Clin Pract Urol 2006;3:306-307.
64.
Orsted DD, Bojesen SE, Kamstrup PR, Nordestgaard BG: Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality. Eur Urol 2013;64:384-393.
65.
Roobol MJ, Steyerberg EW, Kranse E, et al.: A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85.
66.
Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J: Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - results from a prospective, population-based randomized controlled trial. Eur Urol 2007; 51:659-664.
67.
Van Leeuwen PJ, Connolly D, Gavin A, et al.: Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer 2010;46:377-383.
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or...
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
